0.2965
price up icon3.24%   0.0093
 
loading
Schlusskurs vom Vortag:
$0.2872
Offen:
$0.2928
24-Stunden-Volumen:
1.21M
Relative Volume:
0.84
Marktkapitalisierung:
$21.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-26.92M
KGV:
-0.5814
EPS:
-0.51
Netto-Cashflow:
$-18.92M
1W Leistung:
+16.37%
1M Leistung:
+11.34%
6M Leistung:
-67.23%
1J Leistung:
-79.69%
1-Tages-Spanne:
Value
$0.2852
$0.3099
1-Wochen-Bereich:
Value
$0.2501
$0.3111
52-Wochen-Spanne:
Value
$0.18
$2.39

Cel-Sci Corp. Stock (CVM) Company Profile

Name
Firmenname
Cel-Sci Corp.
Name
Telefon
703-506-9460
Name
Adresse
8229 Boone Boulevard, Suite 802, Vienna, VA
Name
Mitarbeiter
0
Name
Twitter
@CelSciCorp
Name
Nächster Verdiensttermin
2025-02-18
Name
Neueste SEC-Einreichungen
Name
CVM's Discussions on Twitter

Vergleichen Sie CVM mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CVM
Cel-Sci Corp.
0.2965 21.43M 0 -26.92M -18.92M -0.51
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.47 125.74B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
599.76 61.57B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
600.51 36.40B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
242.61 30.36B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
256.16 24.89B 3.81B -644.79M -669.77M -6.24

Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2020-01-13 Eingeleitet H.C. Wainwright Buy
2015-03-02 Eingeleitet Dawson James Buy

Cel-Sci Corp. Aktie (CVM) Neueste Nachrichten

pulisher
06:33 AM

Cel-Sci Corp [AMEX: CVM] Sees Increase in Stock Value - knoxdaily.com

06:33 AM
pulisher
Apr 24, 2025

US biotech seeks Saudi approval for cancer treatment - Arabian Gulf Business Insight | AGBI

Apr 24, 2025
pulisher
Apr 23, 2025

CEL-SCI to seek Saudi approval for cancer treatment - Investing.com

Apr 23, 2025
pulisher
Apr 23, 2025

CEL-SCI Corp To File For Regulatory Approval Of Multikine In Saudi Arabia - marketscreener.com

Apr 23, 2025
pulisher
Apr 23, 2025

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market - Yahoo Finance

Apr 23, 2025
pulisher
Apr 23, 2025

Market Momentum Report: Cel-Sci Corp (CVM)’s Positive Close at 0.27 - DWinneX

Apr 23, 2025
pulisher
Apr 23, 2025

Its Stock Has Paid Off Big Time For Cel-Sci Corp - Sete News

Apr 23, 2025
pulisher
Apr 22, 2025

An Analysis of Cel-Sci Corp (CVM)’s Potential Price Growth - knoxdaily.com

Apr 22, 2025
pulisher
Apr 22, 2025

Parsons Corp [PSN] Investment Appeal on the Rise - knoxdaily.com

Apr 22, 2025
pulisher
Apr 22, 2025

Cel-Sci Corp (CVM) presents a great opportunity, but the stock is slightly overvalued - uspostnews.com

Apr 22, 2025
pulisher
Apr 22, 2025

StockNews.com Initiates Coverage on CEL-SCI (NYSE:CVM) - Defense World

Apr 22, 2025
pulisher
Apr 11, 2025

CEL-SCI's Multikine (CVM) Shows Promising Survival Rates in Head and Neck Cancer Study - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Apr 11, 2025
pulisher
Apr 09, 2025

CVM stock touches 52-week low at $0.18 amid sharp annual decline - Investing.com Australia

Apr 09, 2025
pulisher
Apr 09, 2025

CVM stock touches 52-week low at $0.18 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 08, 2025

Breakthrough Cancer Study: New Data Shows 306% Survival Boost for Multikine Treatment - Stock Titan

Apr 08, 2025
pulisher
Apr 06, 2025

CEL-SCI (NYSE:CVM) Now Covered by StockNews.com - Defense World

Apr 06, 2025
pulisher
Mar 31, 2025

CVM stock touches 52-week low at $0.23 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

CVM stock touches 52-week low at $0.23 amid sharp annual decline - Investing.com Australia

Mar 31, 2025
pulisher
Mar 29, 2025

CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com - Defense World

Mar 29, 2025
pulisher
Mar 24, 2025

Breakthrough: New Cancer Drug Delivers 95% Quality of Life Improvement for Head & Neck Patients - Stock Titan

Mar 24, 2025
pulisher
Mar 21, 2025

CVM stock touches 52-week low at $0.26 amid sharp annual decline - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

CVM stock touches 52-week low at $0.26 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Cel-Sci Corp (CVM) Volatility Hits 12.01%: What Good Investors Need To Be Aware Of - Stocks Register

Mar 21, 2025
pulisher
Mar 18, 2025

CEL-SCI announces closing of $2.5 million offering -March 18, 2025 at 05:23 pm EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

CEL-SCI Secures $2.5M Funding: Major Push for FDA-Designated Cancer Immunotherapy - StockTitan

Mar 18, 2025
pulisher
Mar 18, 2025

Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 18, 2025
pulisher
Mar 17, 2025

CEL-SCI Secures Critical Funding for FDA-Approved Head & Neck Cancer Treatment Study - StockTitan

Mar 17, 2025
pulisher
Mar 17, 2025

CEL-SCI advances in head and neck cancer treatment study - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Mar 17, 2025
pulisher
Mar 17, 2025

CEL-SCI advances in head and neck cancer treatment study By Investing.com - Investing.com UK

Mar 17, 2025
pulisher
Mar 17, 2025

CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine - Yahoo Finance

Mar 17, 2025
pulisher
Mar 15, 2025

Cel-Sci Corp (CVM) Recovers 5.85% From Low: Are We There Yet? - Stocks Register

Mar 15, 2025
pulisher
Mar 14, 2025

Major Breakthrough: JAMA Study Shows Multikine Triples Survival Rates in Head and Neck Cancer - StockTitan

Mar 14, 2025
pulisher
Mar 13, 2025

CEL-SCI (NYSE:CVM) Coverage Initiated at StockNews.com - Defense World

Mar 13, 2025
pulisher
Mar 10, 2025

CVM stock touches 52-week low at $0.31 amid sharp annual decline - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

CVM stock touches 52-week low at $0.31 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 07, 2025

CEL-SCI Announces That NYSE MKT Granted an Extension to Regain Compliance - AOL.com

Mar 07, 2025
pulisher
Mar 06, 2025

CVMCEL-SCI Corp Latest Stock News & Market Updates - Stock Titan

Mar 06, 2025
pulisher
Mar 05, 2025

4 Biotech Stocks To Watch: CVM, NKGN, NBIO, IMUX - DRP Journal

Mar 05, 2025
pulisher
Feb 28, 2025

CVM Stock Hits 52-Week Low at $0.33 Amid Steep Annual Decline - Investing.com Australia

Feb 28, 2025
pulisher
Feb 27, 2025

CVM Stock Hits 52-Week Low at $0.33 Amid Steep Annual Decline By Investing.com - Investing.com South Africa

Feb 27, 2025
pulisher
Feb 20, 2025

CEL-SCI advances Multikine study for head and neck cancer - Investing.com

Feb 20, 2025
pulisher
Feb 20, 2025

CEL-SCI advances Multikine study for head and neck cancer By Investing.com - Investing.com UK

Feb 20, 2025
pulisher
Feb 20, 2025

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial -February 20, 2025 at 08:06 am EST - Marketscreener.com

Feb 20, 2025
pulisher
Feb 20, 2025

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial - Yahoo Finance

Feb 20, 2025
pulisher
Feb 20, 2025

Can This Cancer Drug Triple Patient Survival Rates? New Trial Holds Answer - Stock Titan

Feb 20, 2025
pulisher
Feb 19, 2025

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks - BioSpace

Feb 19, 2025
pulisher
Feb 18, 2025

StockNews.com Begins Coverage on CEL-SCI (NYSE:CVM) - Armenian Reporter

Feb 18, 2025
pulisher
Feb 17, 2025

CEL-SCI (NYSE:CVM) Now Covered by Analysts at StockNews.com - Defense World

Feb 17, 2025

Finanzdaten der Cel-Sci Corp.-Aktie (CVM)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.54
price up icon 2.04%
$68.96
price down icon 2.60%
$32.03
price up icon 1.07%
$36.70
price up icon 10.44%
$120.54
price up icon 4.97%
biotechnology ONC
$256.16
price up icon 2.82%
Kapitalisierung:     |  Volumen (24h):